Report Overview

The US Oral Drugs for Rheumatoid Arthritis Treatment Market was valued at USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, growing at a CAGR of XX% from 2019 to 2028

Rheumatoid Arthritis usually affects the geriatric population, and the prevalence is seen higher in females as compared to males. Therefore, larger cases of this disease can be found in the aged population. There are also several therapeutics and medications that have been developed in recent years, to treat the symptoms of rheumatoid arthritis. The most commonly used oral drugs are disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and biologic drugs. Thus, the growing availability and awareness of safer drugs are anticipated to increase the rheumatoid arthritis drugs market. Rheumatoid Arthritis treatment is generally lifelong and can require medication changes. No single DMARD(Disease Modifying Anti-Rheumatoid Drugs) is superior as an initial treatment; however, methotrexate is commonly used. As per a publication in Morbidity and Mortality Weekly Report, by 2040, an estimated 78 million (26% of United States adults) aged 18 years or older are projected to have doctor-diagnosed arthritis. This shows a steady growth in arthritic cases, supporting the expected growth of oral drugs in the market



Market Growth Drivers

The key factors propelling the growth of the oral drug for the rheumatoid arthritis treatment market are the new developments in the field of new biosimilars. The rising prevalence of Rheumatoid Arthritis and an increase in the acceptance of biopharmaceuticals will fuel the growth of this market